In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Claritin, Pseudoephedrine Sales Impact Schering Consumer Health Revenue

This article was originally published in The Tan Sheet

Executive Summary

Sales for the Clarinex and Claritin prescription business decreased 4% during the third quarter to $233 mil., Schering-Plough Executive VP - Global Pharmaceuticals President Carrie Cox stated in an Oct. 24 third-quarter earnings call

You may also be interested in...



Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”

Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement

Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”

Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement

Chattem’s Financing Strategy Keeps Door Open For Acquisitions

Chattem remains in the hunt for acquisitions because its preferred financing strategy continues to be attractive even with lending activity slowed worldwide, according to President and Chief Operating Officer Bob Bosworth

Topics

UsernamePublicRestriction

Register

PS098773

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel